Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 19/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4350356 | 0.91 | TRPV1 (0.54) | TRPV1NTRK1CYP3A4CYP2D6 | |
| SCHEMBL4348649 | 0.91 | TRPV1 (0.54) | TRPV1NTRK1CYP3A4CYP2D6 | |
| SCHEMBL4354864 | 0.91 | TRPV1 (0.53) | TRPV1NTRK1CYP3A4CYP2D6 | |
| SCHEMBL4359756 | 0.90 | TRPV1 (0.65) | TRPV1NTRK1 | |
| SCHEMBL4788004 | 0.88 | TRPV1 (0.51) | TRPV1CYP2D6 | |
| SCHEMBL4343205 | 0.88 | TRPV1 (0.51) | TRPV1NTRK1CYP3A4CYP2D6 | |
| SCHEMBL4350187 | 0.87 | TRPV1 (0.64) | TRPV1CYP3A4CYP2D6 | |
| SCHEMBL4350468 | 0.86 | TRPV1 (0.65) | TRPV1CYP3A4CYP2D6 | |
| SCHEMBL4788249 | 0.86 | TRPV1 (0.65) | TRPV1CYP3A4CYP2D6 | |
| SCHEMBL4345003 | 0.85 | TRPV1 (0.51) | TRPV1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622493-B2 | Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof | ABBOTT LABORATORIES (US) | 2009-11-24 | — | — | US | claimed |
| EP-2012778-A2 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | Abbott Laboratories (US) | 2009-01-14 | — | — | EP | claimed |
| US-20070249614-A1 | Antagonists of the Vanilloid Receptor Subtype 1 (VR1) and Uses Thereof | ABBVIE INC. | 2007-10-25 | — | — | US | claimed |
| WO-2007121299-A2 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-10-25 | — | — | WO | claimed |
| US-8598220-B2 | Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof | ABBVIE INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-7622493-B2 | Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof | ABBOTT LABORATORIES (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090233953-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-09-17 | — | — | US | disclosed |
| US-20070249614-A1 | Antagonists of the Vanilloid Receptor Subtype 1 (VR1) and Uses Thereof | ABBVIE INC. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233953-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | OPRL1, AVPR1A, TRPV1 | TRPV1 3/4885NTRK1 548/4885CYP3A4 1720/4885 |
| US-20070249614-A1 | Antagonists of the Vanilloid Receptor Subtype 1 (VR1) and Uses Thereof | OPRL1, AVPR1A, AVPR1B | TRPV1 4/4885NTRK1 569/4885CYP3A4 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.